Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ibutilide Fumarate

FDA-approved product (injectable, injection), marketed as Corvert, Ibutilide Fumarate.

Registered studies
10
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Ibutilide Fumarate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiac arrhythmia

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Antiarrhythmics, class iii
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA33.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli30.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

10registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ibutilide Fumarate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ibutilide Fumarate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pulsed Field Ablation Outcomes With Efficacy and Randomization in Atrial Fibrillation (POWER-AF)

    NCT07601763 · start 2025-04-16

    Registered record
    Registry ID
    NCT07601763
    Conditions
    Atrial Fibrillation (AF); Atrial Fibrillation Ablation; Atrial Fibrillation Recurrent; Pulsed Field Ablation; Radiofrequency Catheter Ablation
    Interventions
    Pulsed field ablation; Radiofrequency ablation alone; Pulsed field ablation system
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-04-16
    Completion
    2028-11-30
    Enrolment
    1,574

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation (AF); Atrial Fibrillation Ablation; Atrial Fibrillation Recurrent; Pulsed Field Ablation +1 more
    InterventionPulsed field ablation; Radiofrequency ablation alone; Pulsed field ablation system
    PhaseNot applicable
    Registry statusRecruiting

  • Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening

    NCT04675788 · start 2021-09-02

    Registered record
    Registry ID
    NCT04675788
    Conditions
    Long QT Syndrome; Abnormalities, Drug-Induced
    Interventions
    Progesterone; Ibutilide; Testosterone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-09-02
    Completion
    2025-04-16
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLong QT Syndrome; Abnormalities, Drug-Induced
    InterventionProgesterone; Ibutilide; Testosterone; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

    NCT03834883 · start 2019-03-26

    Registered record
    Registry ID
    NCT03834883
    Conditions
    Long QT Syndrome; Abnormalities, Drug-Induced
    Interventions
    Progesterone; Ibutilide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-03-26
    Completion
    2024-05-23
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLong QT Syndrome; Abnormalities, Drug-Induced
    InterventionProgesterone; Ibutilide
    PhasePhase 4
    Registry statusCompleted

  • ECGI in Patients With Persistent Atrial Fibrillation

    NCT03836092 · start 2018-02-23

    Registered record
    Registry ID
    NCT03836092
    Conditions
    Atrial Fibrillation
    Interventions
    Radiofrequency ablation
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-02-23
    Completion
    2022-04-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionRadiofrequency ablation
    PhaseNot recorded
    Registry statusCompleted

  • ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization

    NCT03370536 · start 2017-11-01

    Registered record
    Registry ID
    NCT03370536
    Conditions
    Atrial Fibrillation; Persistent Atrial Fibrillation
    Interventions
    CardioInsight ECGI Mapping System; AF ablation; Ibutilide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2017-11-01
    Completion
    2018-07-18
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Persistent Atrial Fibrillation
    InterventionCardioInsight ECGI Mapping System; AF ablation; Ibutilide
    PhaseNot applicable
    Registry statusTerminated

  • Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

    NCT02513940 · start 2016-05

    Registered record
    Registry ID
    NCT02513940
    Conditions
    Long QT Syndrome
    Interventions
    Testosterone; Progesterone; Placebo; Ibutilide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-05
    Completion
    2017-10-19
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLong QT Syndrome
    InterventionTestosterone; Progesterone; Placebo; Ibutilide
    PhasePhase 4
    Registry statusCompleted

  • Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening

    NCT01929083 · start 2013-04

    Registered record
    Registry ID
    NCT01929083
    Conditions
    Prolonged QT Interval in EKG and Sudden Death
    Interventions
    Progesterone; Placebo; Ibutilide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-04
    Completion
    2014-06
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProlonged QT Interval in EKG and Sudden Death
    InterventionProgesterone; Placebo; Ibutilide
    PhasePhase 2
    Registry statusCompleted

  • Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation

    NCT01447862 · start 2011-10

    Registered record
    Registry ID
    NCT01447862
    Conditions
    Atrial Fibrillation
    Interventions
    Brinavess (Vernakalant); Corvert (Ibutilide)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-10
    Completion
    2015-05
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionBrinavess (Vernakalant); Corvert (Ibutilide)
    PhasePhase 4
    Registry statusCompleted

  • Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

    NCT01014741 · start 2009-10

    Registered record
    Registry ID
    NCT01014741
    Conditions
    Persistent Atrial Fibrillation
    Interventions
    Ibutilide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-10
    Completion
    2015-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPersistent Atrial Fibrillation
    InterventionIbutilide; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Ibutilide Administration During Pulmonary Vein Ablation

    NCT00589992 · start 2007-10

    Registered record
    Registry ID
    NCT00589992
    Conditions
    Atrial Fibrillation; Pulmonary Vein Ablation
    Interventions
    Ibutilide fumarate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2007-10
    Completion
    2016-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Pulmonary Vein Ablation
    InterventionIbutilide fumarate
    PhaseNot applicable
    Registry statusUnknown